Results 21 to 30 of about 399,116 (301)

A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling [PDF]

, 2019
It is well known that the treatment effect of a molecularly targeted agent (MTA) may vary dramatically, depending on each patient's biomarker profile. Therefore, for a clinical trial evaluating MTA, it is more reasonable to evaluate its treatment effect ...
Cao, Sha, Guo, Beibei, Han, Yan, Zang, Yong, Zhang, Chi   +4 more
core   +3 more sources

A simulation study on estimating biomarker–treatment interaction effects in randomized trials with prognostic variables

Trials, 2018
Background To individualize treatment decisions based on patient characteristics, identification of an interaction between a biomarker and treatment is necessary.
Bernhard Haller, Kurt Ulm
doaj   +1 more source

Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 8710 [PDF]

, 2017
No abstract ...
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, Asano, Ferro, Gondo, Grenader, Guthrie, Krane, Linton, Lorente, Mitchell, Ojerholm, Templeton, Viers   +12 more
core   +1 more source

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. [PDF]

, 2017
Background Circulating tumor cells (CTCs) and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in CTCs and tumor tissue were evaluated as prognostic or predictive markers of CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE) versus ...
Baeten, Kurt, Connelly, Mark C, D'Haese, David, Flynt, Amy, Gross, Steve, McCleod, Michael, Morano, Carrie, Peek, Victoria L, Polzer, John, Raddad, Eyas, Repollet, Madeline, Roberson, Stephanie, Salgia, Ravi, Sanders, Renouard, Spigel, David R, Stille, John R, Um, Suzane L, Weaver, R Waide, Wijayawardana, Sameera R, Yan, S Betty   +19 more
core   +1 more source

Prognostic impact of autophagy biomarkers for cutaneous melanoma.

Frontiers in Oncology, 2016
Prognosis and survival for malignant melanoma is highly dependent on early diagnosis and treatment. While the American Joint Committee on Cancer (AJCC) criteria provides a means of staging melanomas and guiding treatment approaches, it is unable to ...
Diana Yao Li Tang, Robert Ellis, Robert Ellis, Penny Lovat   +3 more
doaj   +1 more source

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. [PDF]

, 2020
BackgroundTransforming growth factor beta (TGF-β) signalling is involved in the development of hepatocellular carcinoma (HCC). We followed changes in biomarkers during treatment of patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib ...
Benhadji, Karim A, Cleverly, Ann, Estrem, Shawn T, Faivre, Sandrine, Gane, Ed, Giannelli, Gianluigi, Kelley, Robin K, Lahn, Michael M, Man, Michael, Paradis, Valerie, Raymond, Eric, Santoro, Armando, Smith, Claire, Wang, Shuaicheng   +13 more
core   +2 more sources

Prognostic and Predictive Biomarkers in Gliomas [PDF]

International Journal of Molecular Sciences, 2021
Gliomas are the most common central nervous system tumors. New technologies, including genetic research and advanced statistical methods, revolutionize the therapeutic approach to the patient and reveal new points of treatment options. Moreover, the 2021 World Health Organization Classification of Tumors of the Central Nervous System has fundamentally ...
Paulina Śledzińska, Marek G. Bebyn, Jacek Furtak, Janusz Kowalewski, Marzena A. Lewandowska   +4 more
openaire   +2 more sources

Identification of a prognostic biomarker predicting biochemical recurrence and construction of a novel nomogram for prostate cancer

Frontiers in Oncology, 2023
BackgroundBiochemical recurrence (BCR) is common in prostate cancer (PCa), but its prediction is based predominantly on clinicopathological characteristics with low accuracy.
Zhaojun Yu, Zhaojun Yu, Haichao Chao, Fanghua Xu, Huanhuan Deng, Huanhuan Deng, Leihong Deng, Zhen Song, Tao Zeng   +8 more
doaj   +1 more source

Integrative analysis of the colorectal cancer proteome : potential clinical impact [PDF]

, 2016
Peer ...
Alnabulsi, Abdo, Murray, Graeme I.
core   +2 more sources

Pan-cancer evaluation of clinical value of mitotic network activity index (MNAI) and its predictive value for immunotherapy

Frontiers in Oncology, 2023
Increased mitotic activity is associated with the genesis and aggressiveness of many cancers. To assess the clinical value of mitotic activity as prognostic biomarker, we performed a pan-cancer study on the mitotic network activity index (MNAI ...
Xuanyu Mao, Xuanyu Mao, Yimeng Cai, Yimeng Cai, Sarah Long, Jesus Perez-Losada, Jesus Perez-Losada, Jian-Hua Mao, Jian-Hua Mao, Hang Chang, Hang Chang   +10 more
doaj   +1 more source